Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Celligent Biotechnology Limited is navigating the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This indicates a targeted effort to secure its technical developments. The company is currently focused on resolving this single outstanding matter to advance its application through the patent office.
The prosecution of this portfolio is handled by 1 distinct examiner and 1 distinct art unit. This centralized structure shows that the company's technology is being evaluated within a specific technical silo. For the practitioner, this lack of diversity in examiners and art units simplifies the prosecution landscape, as there is only one set of departmental standards to navigate.
BUNKER, AMY M is the busiest examiner assigned to this portfolio. This individual is currently managing the 1 busiest examiner pending office action. Because BUNKER, AMY M is responsible for the company's entire pending workload, the success of the current prosecution cycle depends entirely on this examiner. A deep understanding of the specific preferences of BUNKER, AMY M is essential for resolving the 1 pending office action efficiently.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUNKER, AMY M | 1 | 29.1% | +45.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18269625 | BIOCHIP FOR SPATIAL TRANSCRIPTOMIC ANALYSIS, MANUFACTURING METHOD THEREFOR AND APPLICATION THEREOF | BUNKER, AMY M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18269625 | BIOCHIP FOR SPATIAL TRANSCRIPTOMIC ANALYSIS, MANUFACTURING METHOD THEREFOR AND APPLICATION THEREOF | BUNKER, AMY M | — |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18269625 | BIOCHIP FOR SPATIAL TRANSCRIPTOMIC ANALYSIS, MANUFACTURING METHOD THEREFOR AND APPLICATION THEREOF | BUNKER, AMY M | 1684 | §101§102§103§112Other | Final Rejection | — | Pending | Jul 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCelligent Biotechnology Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Amy M Bunker has the most, with 1 of Celligent Biotechnology Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
